Clin2
NCT06712017Likely a fitEnrolling by invitation

Radioactive beads treatment for liver cancer in China

Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-Resectable

Part of Cancer, Digestive system clinical trials.

This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be 18 years old or older
  • You must have a confirmed diagnosis of liver cancer (HCC)
  • You were treated with SIR-Spheres (yttrium-90) between January 1, 2023, and June 30, 2024
  • You had at least one check-up within 6 months after treatment to see how the tumor responded

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06707233Recruiting· Phase 2
Y-90 radioembolization for large liver cancer (over 7 cm)

This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.

Guangzhou, Guangdong
NCT07070076Recruiting
Y-90 therapy vs chemo infusion for liver cancer

This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.

Guangzhou, Guangdong
NCT07110233Not yet recruiting
Y-90 radiation for liver cancer not treatable by surgery or ablation

This study tests whether a targeted radiation treatment called Y-90 segmentectomy can shrink liver tumors. It is for people with one to three small liver tumors that cannot be removed by surgery or destroyed by heat or cold (ablation).

San Francisco, California
NCT07476651Recruiting
Study of a scout dose of resin microspheres for liver cancer

This trial is testing a low 'scout' dose of tiny radioactive beads (resin microspheres) given into the liver to treat liver cancer. The goal is to see if this approach is safe and helps patients with certain types of liver cancer that cannot be surgically removed.

Seoul
NCT07663487Not yet recruiting· Phase 2
Radiation therapy before liver transplant or surgery for liver cancer

This trial tests if a targeted radiation treatment, called SIRT, can shrink liver tumors enough to allow for a liver transplant or surgical removal. It is for people with liver cancer who are not yet eligible for these procedures.

NCT07657273Not yet recruiting· Phase 2
Radioembolization for previously treated liver cancer

This trial tests a treatment called yttrium-90 carbon microsphere radioembolization for people with liver cancer that has been previously treated. Tiny radioactive beads are delivered directly to the tumor through the blood vessels to destroy cancer cells from inside. This may be an option if your liver cancer has not spread beyond the liver and you can tolerate the procedure.

Guangzhou, Guangdong

Hear when a new Hepatocellular Carcinoma (HCC) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.